Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 240.00 230.00 250.00 240.00 240.00 240.00 692 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 74.6 15.2 17.6 13.6 162

Eco Animal Health Share Discussion Threads

Showing 901 to 924 of 1150 messages
Chat Pages: 46  45  44  43  42  41  40  39  38  37  36  35  Older
DateSubjectAuthorDiscuss
25/6/2018
20:40
Just an uncrossing auction trade. They always reverse on the trading session after as its not a fair reflection of the market. Same can happen on the upside as on the downside. Happens on lots of illiquid stocks
pireric
25/6/2018
11:15
Some after hours transactions at 482p on Friday. Someone who knows what this means might be able to explain. I was beginning to think there was a leaky results ship about. Been hit a few times lately where the price dropped away ahead of poor results...hope it doesn’t happen again here!
steve3sandal
25/6/2018
08:46
Some very strange movements in the share price When did it drop 25p? Thought it finished flat on Friday? Anyhow, it seems to have jumped straight back on zero volume today. Weird!
audigger
20/6/2018
15:41
I, too, am looking forward to encouragingly good results, but would also like to learn more about: - the gradual replacement of distributors by EAH's own staff, which would increase margins. - a possible second factory for the production of Aivlosin, reducing dependence on a single unit in China. - increasing prices achieved for Aivlosin and improving EBIDTA margins. - an update on the authorisation of Aivlosin for 'other species'. _ more about the ECO-PHARM joint venture and the business scope and opportunities for their range of vaccine products.
aimingupward2
19/6/2018
20:24
Back down to the trough of early this year. Results should be out soon and show nice numbers. To add further, or not, that's the question Expecting EPS of 20p, so +25% y/y, obviously this being negatively impacted by registration costs needing to be amortised extremely quickly, and so EBITDA the more telling figure. Should be good and £ weakness hopefully already flowing into an extra tailwind for this financial year.
pireric
05/6/2018
12:02
If history is our guide I think PL will be pleased to see the cash pile increase. Mostly reinvest cashflows, pay out a little, save a little. Same story at Anpario. Been watching this play out for years, since Amati VCT Investment. I try to do the same!
steve3sandal
05/6/2018
11:02
Take that as a no :0). Happy enough if these are in line with expectations as last year was a very strong base period to perform against (FX tailwinds turning to headwinds etc). Still wondering what on earth they're going to do with the cash pile, any thoughts anyone? What would you like to see them do?
pireric
02/6/2018
09:22
Anyone seen the Peel hunt note from weds/thurs where they reiterated their buy rating?
pireric
26/5/2018
12:28
Possibly; unless results are in line then I guess they don't need to release one. I need to do some synergy work around this, Genus and Anpario. I'm wondering if a deal between any two of them is a possibility. Know some of the board members are scattered around (e.g. P Lawrence sits on the ANP board).
pireric
25/5/2018
11:47
Interesting post pireric. Last year ECO released a trading statement on 15th May (before the FY results), so aren't we due one now?
jimbowen30
23/5/2018
18:08
Post 836 by rzbrdbe was the one, very informative
audigger
23/5/2018
18:00
My plea for a surge towards 700p appears to have had the opposite effect. Over the years I've called the share price movement quite well but not in recent times. I really didn't expect it to pull back from 680 to here given the solid growth in revenues and bottom line. Assuming margins are still ok and the demand is still there, then so long as they can make enough Aivlosin all should be good. Somebody posted an insightful analysis last year as to why they may be meeting some challenges, worth another read when I can find it.
audigger
23/5/2018
14:32
Getting cheaper! Wish management here come out with a strategy for their excess cash at the FY results. It's a big unknown but should really be a positive. Wouldn't say a buyback given the liquidity of the stock, but special Divi, acquisition, or turbocharging r+d would be appreciated!!
pireric
21/5/2018
20:08
Good spot pireric. Long overdue a wave of good news to propel this to 700p!
audigger
20/5/2018
15:22
Some of you might know that Ecuphar, a company that reversed into Animalcare has a major part of its production animals pharma business distributing Aivlosin. It's one of their top 10 products for that segment. So potentially some decent read through from ANCRs recent results commentary: "The £13.2m year-on-year increase is attributable to an additional £7.6m of sales derived from acquisition growth, with the balance generated through organic growth within the Ecuphar business. Organic growth was driven by a number of factors including a very strong performance from sales into the Production Animals market, as well as strong growth from Companion Animals. In the division our top 20 pharmaceutical products, which account for 51% of this division's total sales grew by 15.1% in 2017."
pireric
11/5/2018
16:04
Above expectations would be most welcome!
audigger
11/5/2018
15:02
Next week for a pre-release definitely a possibility. In-line + confident outlook what I'm expecting
pireric
11/5/2018
14:48
Somebody has just put well over £100,000 into a purchase - shows a lot of confidence. I wonder if we will get any announcement ahead of the results which are due in about four weeks time.
aimingupward2
24/4/2018
20:53
Standard Life taking up some slack stock by the looks of it
pireric
20/4/2018
19:08
Indeed. Looking spritely :0)
pireric
19/4/2018
16:30
370k traded at 545p today. Might clear the tubes a bit.
sspurt
03/4/2018
18:57
Absolutely not impossible if I'm right.... Annual report 2016, Pharmgate LLC - the US operations. Bear in mind 50:50 JV. Sales £4.224m Expenses £0.892m Canadian version of the JV, 2016 Sales £2.681m Expenses £0.247m Both very profitable ventures, clearly. So looks like very solid good news. Margins are excellent and 2016 wasn't a one-off year either. So if they scale this right and execute well, looks like it could be 10-15% accretive to EBITDA within 3 years or so
pireric
03/4/2018
17:57
Well it won’t be bad. Happy to hold and wait.
topvest
03/4/2018
08:23
Good to learn of something positive coming along, although it’s near impossible to judge quite what impact this will have on the overall business.
aimingupward2
Chat Pages: 46  45  44  43  42  41  40  39  38  37  36  35  Older
ADVFN Advertorial
Your Recent History
LSE
EAH
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200810 08:14:44